Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin, MD, MPH

The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.:

Source: Neurology Read More

Previous PostFlat Head Positioning Before Thrombectomy Linked to Better Long-Term Stroke Outcomes
Next PostHow Phase 3 TEMPLE Results Support CGRP Inhibitors as First-Line Preventives for Migraine: Jessica Ailani, MD

Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin, MD, MPH

Previous PostFlat Head Positioning Before Thrombectomy Linked to Better Long-Term Stroke Outcomes

Next PostHow Phase 3 TEMPLE Results Support CGRP Inhibitors as First-Line Preventives for Migraine: Jessica Ailani, MD

Related Posts

<![CDATA[Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD]]>

<![CDATA[Up to 8 Years of Ofatumumab Treatment Demonstrates Stable Long-term Safety Profile in Relapsing Multiple Sclerosis]]>

<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>

Categories